MAP2K7 and lung carcinoma: Molina-Arcus et al. [73] found that co-targeting mTOR/IGF1R and either MEK or KRASG12C showed efficacy in mouse models of KRAS-mutant lung cancer, with less toxicity noted in the G12C inhibitor combination.